Robbins LLP Urges GOSS Stockholders to Contact the Firm for Information About the Class Action Against Gossamer Bio, Inc.
Gossamer Bio, Inc. (GOSS)
Last gossamer bio, inc. earnings: 3/24 07:00 am
Check Earnings Report
Company Research
Source: Business Wire
SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Gossamer Bio, Inc. (NASDAQ: GOSS) securities between June 16, 2025 and February 20, 2026. Gossamer is a clinical stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension (PH) associated with interstitial lung disease.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.What is the class period? June 16, 2025 – February 20, 2026What are the allegations? Robbins LLP is Investigating Allegations that Gossamer Bio, Inc. (GOSS) Misled Investors Regarding the Viability of its PROSERA StudyAccording to the complaint, during the class period, defendants provided investors with material information concerning Gossamer’s Phase 3 PROSERA study evaluating seralutinib for the treatment of pulmonary arterial h
Show less
Read more
Impact Snapshot
Event Time:
GOSS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GOSS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GOSS alerts
High impacting Gossamer Bio, Inc. news events
Weekly update
A roundup of the hottest topics
GOSS
News
- Pomerantz LLP Informs Shareholders of Class Action Against Gossamer Bio, Inc. – GOSSACCESS Newswire
- Gossamer Bio, Inc. (GOSS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud LawsuitPR Newswire
- GOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Concealing Placebo Response Risks: Levi & KorsinskyPR Newswire
- GOSS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Gossamer Bio, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!ACCESS Newswire
- Pomerantz LLP Informs Shareholders of Class Action Filing Against Gossamer Bio, Inc. – GOSSACCESS Newswire
GOSS
Earnings
- 3/17/26 - Miss
GOSS
Sec Filings
- 4/24/26 - Form ARS
- 4/24/26 - Form DEFA14A
- 4/24/26 - Form DEF
- GOSS's page on the SEC website